Indian benchmark indices Nifty 50 and Sensex ended the previous trade session in the red. Nifty 50 closed at 22,552.50, while ...

The company's subsidiary has launched the Yesintek biosimilar in the United States. This is one of the first Stelara ...

Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...

The company, along with its subsidiary NTPC Green Energy, has entered into multiple MoUs with the Madhya Pradesh government ...

Stocks including NTPC, LIC of India, ONGC, Biocon, SBI Life, UPL, Shree Cement, SBI Cards, IREDA and Welspun Corp will be in ...

NTPC along with its arm NTPC Green Energy signed multiple MoUs with Madhya Pradesh government to invest over Rs 2 lakh crore ...

A number of stocks are set to be in focus during the coming session on Dalal Street, including NTPC, NTPC Green, SBI Card and ...

The NSE Nifty 50 ended 1.06% lower at 22,553.35, while the BSE Sensex closed 1.14% down at 74,454.41 on Monday.

Shares of firms like Biocon, LIC, NTPC Green, IREDA, Texmaco Rail, and others will be in focus on Tuesday's trade ...

YESINTEK is approved for Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, offering a ...

MUMBAI:  Biocon Biologics Ltd has announced the US launch of Yesintek  (ustekinumab-kfce), one of the first biosimilars to Janssen's Stelara® to enter the American market. The biosimilar, approved by ...

Biocon Biologics (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon (BSE code: 532523, NSE: BIOCON), today announced that YESINTEK (ustekinumab-kfce) is now available to ...